Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Combinations of single nucleotide polymorphisms WWOX‐rs13338697, GALNT14‐rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma

Combinations of single nucleotide polymorphisms WWOX‐rs13338697, GALNT14‐rs9679162 and rs6025211... 1INTRODUCTIONWorldwide, hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed solid cancer and the third leading cause of cancer‐related mortality. If HCC cannot be completely removed, it usually grows very rapidly, resulting in a short overall survival (OS), ranging from 4 to 7 months. In recent years, owing to the advance of clinical staging systems, the therapeutic strategy of HCC has improved drastically, with many novel therapeutic modalities under clinical investigation. At this time, complete remission can be achieved for HCC patients by either surgical removal or nonsurgical ablation if diagnosed in the early stage, albeit a high recurrent rate of approximately 70% remains. Liver transplantation is considered to be the best treatment in some selected patients who fulfilled designated criteria, because the tumor and adjacent microinvasion were completely removed and most importantly, the cirrhotic liver was replaced. On the other hand, for patients with unresectable HCC, it is still debatable as to which treatment should be considered the “standard therapy.” In HCC patients without main portal vein thrombosis (PVT) or extrahepatic metastasis, namely Barcelona Clinical Liver Cancer (BCLC) stage B, transcatheter arterial chemoembolization (TACE) is believed to be an effective palliative treatment. For patients with BCLC stage C, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Asia-Pacific Journal of Clinical Oncology Wiley

Combinations of single nucleotide polymorphisms WWOX‐rs13338697, GALNT14‐rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma

Loading next page...
1
 
/lp/wiley/combinations-of-single-nucleotide-polymorphisms-wwox-rs13338697-Mg1QP10oLB

References (41)

Publisher
Wiley
Copyright
Copyright © 2018 John Wiley & Sons Australia, Ltd
ISSN
1743-7555
eISSN
1743-7563
DOI
10.1111/ajco.12745
pmid
28695683
Publisher site
See Article on Publisher Site

Abstract

1INTRODUCTIONWorldwide, hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed solid cancer and the third leading cause of cancer‐related mortality. If HCC cannot be completely removed, it usually grows very rapidly, resulting in a short overall survival (OS), ranging from 4 to 7 months. In recent years, owing to the advance of clinical staging systems, the therapeutic strategy of HCC has improved drastically, with many novel therapeutic modalities under clinical investigation. At this time, complete remission can be achieved for HCC patients by either surgical removal or nonsurgical ablation if diagnosed in the early stage, albeit a high recurrent rate of approximately 70% remains. Liver transplantation is considered to be the best treatment in some selected patients who fulfilled designated criteria, because the tumor and adjacent microinvasion were completely removed and most importantly, the cirrhotic liver was replaced. On the other hand, for patients with unresectable HCC, it is still debatable as to which treatment should be considered the “standard therapy.” In HCC patients without main portal vein thrombosis (PVT) or extrahepatic metastasis, namely Barcelona Clinical Liver Cancer (BCLC) stage B, transcatheter arterial chemoembolization (TACE) is believed to be an effective palliative treatment. For patients with BCLC stage C,

Journal

Asia-Pacific Journal of Clinical OncologyWiley

Published: Jan 1, 2018

Keywords: ; ; ;

There are no references for this article.